X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (725) 725
Publication (76) 76
Book Review (24) 24
Book Chapter (7) 7
Conference Proceeding (1) 1
Patent (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (495) 495
index medicus (373) 373
oncology (335) 335
hematology (260) 260
rituximab (225) 225
non-hodgkins-lymphoma (211) 211
refractory low-grade (186) 186
female (180) 180
male (179) 179
lymphomas (172) 172
middle aged (169) 169
cancer (159) 159
chemotherapy (157) 157
follicular lymphoma (152) 152
aged (151) 151
adult (148) 148
lymphoma (143) 143
antibodies, monoclonal - therapeutic use (137) 137
chronic lymphocytic-leukemia (126) 126
antineoplastic agents - therapeutic use (125) 125
b-cell lymphoma (120) 120
treatment outcome (115) 115
care and treatment (112) 112
radioimmunotherapy (109) 109
antineoplastic combined chemotherapy protocols - therapeutic use (105) 105
refractory (100) 100
phase-ii trial (99) 99
anti-cd20 monoclonal-antibody (97) 97
ibritumomab tiuxetan radioimmunotherapy (97) 97
therapy (91) 91
immunotherapy (80) 80
animals (78) 78
transplantation (77) 77
lymphoma, non-hodgkin - drug therapy (74) 74
monoclonal antibodies (73) 73
non-hodgkin's lymphomas (73) 73
aged, 80 and over (68) 68
phase-ii (68) 68
clinical trials as topic (65) 65
iodine i-131 tositumomab (64) 64
medicine & public health (63) 63
pharmacology & pharmacy (63) 63
refractory materials (62) 62
relapsed (62) 62
antibodies, monoclonal, murine-derived (60) 60
recurrence (59) 59
leukemia (58) 58
research (57) 57
clinical trials (56) 56
disease-free survival (55) 55
prognosis (55) 55
bone-marrow-transplantation (53) 53
stem-cell transplantation (53) 53
analysis (52) 52
health aspects (52) 52
hemic and lymphatic diseases (52) 52
radioimmunotherapy - methods (50) 50
immunology (49) 49
stem cells (49) 49
antineoplastic agents (48) 48
non-hodgkin-lymphoma (48) 48
drug therapy (47) 47
mantle cell lymphoma (47) 47
review (47) 47
lymphoma, b-cell - drug therapy (46) 46
patients (46) 46
survival (46) 46
lymphocytes b (45) 45
toxicity (45) 45
t cells (44) 44
non-hodgkin's lymphoma (43) 43
antibodies, monoclonal - administration & dosage (42) 42
antimitotic agents (42) 42
bortezomib (42) 42
cyclophosphamide (42) 42
non-hodgkin lymphoma (42) 42
term-follow-up (42) 42
trial (42) 42
plus rituximab (41) 41
retrospective studies (41) 41
progression-free survival (40) 40
multiple myeloma (39) 39
tumors (39) 39
bendamustine (38) 38
combined modality therapy (38) 38
stem cell transplantation (38) 38
drug resistance, neoplasm (37) 37
acute myeloid-leukemia (36) 36
apoptosis (36) 36
immune system diseases (36) 36
medicine, research & experimental (36) 36
relapse (36) 36
remission induction (36) 36
antineoplastic combined chemotherapy protocols - administration & dosage (35) 35
lymphoma, non-hodgkin - radiotherapy (35) 35
open-label (35) 35
antigens, cd20 - immunology (34) 34
antineoplastic combined chemotherapy protocols - adverse effects (34) 34
article (34) 34
hematology, oncology and palliative medicine (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2011, Volume 24, Issue 2, pp. 147 - 163
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 05/2018, Volume 11, Issue 5, pp. 403 - 410
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2011, Volume 24, Issue 2, pp. 279 - 293
The exquisite sensitivity of haematological malignancies to targeted radiation make Radioimmunotherapy (RIT) a theoretically attractive therapeutic approach.... 
Hematology, Oncology and Palliative Medicine | Follicular Lymphoma | Anti CD20 | Monoclonal Antibody | Radioimmunotherapy | ACUTE MYELOGENOUS LEUKEMIA | FRACTIONATED RADIOIMMUNOTHERAPY | IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY | FOLLOW-UP | MONOCLONAL-ANTIBODY | B-CELL LYMPHOMA | PHASE-II TRIAL | REFRACTORY LOW-GRADE | NON-HODGKINS-LYMPHOMA | IODINE I-131 TOSITUMOMAB | HEMATOLOGY | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - radiotherapy | Sialic Acid Binding Ig-like Lectin 2 - immunology | Antineoplastic Agents - administration & dosage | Yttrium Radioisotopes - administration & dosage | Antibodies, Monoclonal, Humanized | Radioimmunotherapy - methods | B-Lymphocytes - pathology | Antibodies, Monoclonal - immunology | Yttrium Radioisotopes - immunology | Antigens, CD20 - immunology | Antibodies, Monoclonal, Murine-Derived - immunology | Drug Administration Schedule | Antineoplastic Agents - immunology | Lymphoma, Follicular - pathology | Risk Factors | Lymphoma, Follicular - mortality | Rituximab | Clinical Trials as Topic | Remission Induction | B-Lymphocytes - drug effects | Disease-Free Survival | Animals | Lymphoma, Follicular - immunology | Antibodies, Monoclonal - administration & dosage | Mice | Professional hockey | Lymphomas
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26, pp. 3272 - 3278
Purpose This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series... 
SURVIVAL | DIAGNOSIS | ONCOLOGY | REFRACTORY LOW-GRADE | HIGH-DOSE THERAPY | RITUXIMAB | NON-HODGKINS-LYMPHOMA | I-131 TOSITUMOMAB | INDOLENT | HISTOLOGICAL TRANSFORMATION | CHEMOTHERAPY | ORIGINAL REPORTS | Hema10
Journal Article
Cancer / Radiothérapie, ISSN 1278-3218, 04/2018, Volume 22, Issue 2, pp. 126 - 130
To assess the efficacy of treatment and outcomes of patients with relapsed or refractory follicular lymphoma treated with external beam irradiation. Fifteen... 
Radiothérapie | Efficacité | Relapse-refractory follicular lymphoma | Tolerance | Efficacy | Radiation therapy | Lymphomes folliculaires réfractaires ou en rechute | Tolérance | GUIDELINES | RADIATION | TRIAL | DOSE RADIOTHERAPY | THERAPY | ONCOLOGY | INDOLENT LYMPHOMA | CELL LYMPHOMA | RITUXIMAB | NON-HODGKIN-LYMPHOMA | OUTCOMES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Swiss Medical Weekly, ISSN 1424-7860, 07/2018, Volume 148, Issue 29-30, p. w14635
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2010, Volume 151, Issue 4, pp. 346 - 353
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 5, pp. 746 - 753
Journal Article
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, pp. 569 - 570
Journal Article
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, ISSN 1520-4391, 12/2012, pp. 417 - 425
Patients with advanced follicular lymphoma (FL) have numerous treatment options, including observation, radiotherapy, single-agent or combination chemotherapy,... 
ALLOGENEIC TRANSPLANTATION | LOW-GRADE LYMPHOMA | BONE-MARROW-TRANSPLANTATION | PROGRESSION-FREE SURVIVAL | REFRACTORY LOW-GRADE | LONG-TERM SURVIVAL | NON-HODGKIN-LYMPHOMA | I-131 TOSITUMOMAB | HIGH-DOSE CHEMOTHERAPY | Y-90 IBRITUMOMAB TIUXETAN | HEMATOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES
Journal Article